Skip to main content
Subscribe
Register
Sign in
Membership
Events
Knowledge Center
About
Subscribe
Register
Sign in
Stephen Taub
Latest Articles
Biopharma Funds Are in Sick Bay
Stephen Taub
March 12, 2025
Robert Citrone Has Been Bearish This Year — And Now Discovery Is Net Short U.S. Stocks
Stephen Taub
March 11, 2025
Premium
Tesla’s U-Turn Stuns Hedgies
Stephen Taub
March 10, 2025
Premium
Third Point’s Surprising Pullback on Long Positions
Stephen Taub
March 6, 2025
Premium
Icahn’s Private Fund Posts Another Annual Loss
Stephen Taub
March 5, 2025
Taconic Passes the Hat for New Fund
Stephen Taub
March 4, 2025
David Einhorn’s Cautious Stock Market Stance Has Paid Off
Stephen Taub
March 3, 2025
Premium
Tiger Grandcub Sylebra, a Star in Early ’24, Suffers Big Loss
Stephen Taub
February 27, 2025
Premium
RFK Jr.’s Leadership of HHS Weighs on Biopharma
Stephen Taub
February 26, 2025
Premium
Hedge Funds Still in Love With Amazon
Stephen Taub
February 25, 2025
Premium
Hedging Strategies Demonstrate Their Power
Stephen Taub
February 24, 2025
Premium
Top Performer Sosin Partners Braces for Possible Roadblock
Stephen Taub
February 20, 2025
The Stocks Stan Druckenmiller Just Bought
Stephen Taub
February 19, 2025
Tiger Cub Robert Citrone Gears Up for a Stock Market Correction
Stephen Taub
February 13, 2025
Despite the Administration’s ‘Unconventional Approach,’ Dan Loeb Is Still Bullish for 2025
Stephen Taub
February 6, 2025
A Value-Driven Hedge Fund’s Strong Start
Stephen Taub
February 3, 2025
Premium
How Chris Hohn’s Concentrated Portfolio Fared Last Year
Stephen Taub
January 30, 2025
Loeb Bullish on a Republican Win
Stephen Taub
October 21, 2024
More Articles